WO2004010936A3 - Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders - Google Patents
Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders Download PDFInfo
- Publication number
- WO2004010936A3 WO2004010936A3 PCT/US2003/023430 US0323430W WO2004010936A3 WO 2004010936 A3 WO2004010936 A3 WO 2004010936A3 US 0323430 W US0323430 W US 0323430W WO 2004010936 A3 WO2004010936 A3 WO 2004010936A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dyslipidemia
- treatment
- lipid disorders
- ppar alpha
- selective compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03771907A EP1539136B1 (en) | 2002-07-30 | 2003-07-25 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
JP2004524883A JP4475406B2 (en) | 2002-07-30 | 2003-07-25 | PPARα selective compounds for the treatment of dyslipidemia and other lipid disorders |
DE60322075T DE60322075D1 (en) | 2002-07-30 | 2003-07-25 | PPAR ALPHA SELECTIVE COMPOUNDS FOR THE TREATMENT OF DYSLIPIDEMIA AND OTHER LIPID DISORDERS |
US10/522,259 US7524882B2 (en) | 2002-07-30 | 2003-07-25 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
AU2003256842A AU2003256842B8 (en) | 2002-07-30 | 2003-07-25 | PPAR alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
CA002491733A CA2491733A1 (en) | 2002-07-30 | 2003-07-25 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US39952002P | 2002-07-30 | 2002-07-30 | |
US60/399,520 | 2002-07-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004010936A2 WO2004010936A2 (en) | 2004-02-05 |
WO2004010936A3 true WO2004010936A3 (en) | 2004-08-26 |
Family
ID=31188592
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/023430 WO2004010936A2 (en) | 2002-07-30 | 2003-07-25 | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Country Status (8)
Country | Link |
---|---|
US (1) | US7524882B2 (en) |
EP (1) | EP1539136B1 (en) |
JP (1) | JP4475406B2 (en) |
AT (1) | ATE400564T1 (en) |
AU (1) | AU2003256842B8 (en) |
CA (1) | CA2491733A1 (en) |
DE (1) | DE60322075D1 (en) |
WO (1) | WO2004010936A2 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8362248B2 (en) | 2005-01-10 | 2013-01-29 | Arena Pharmaceuticals, Inc. | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
US8933083B2 (en) | 2003-01-14 | 2015-01-13 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2491733A1 (en) * | 2002-07-30 | 2004-02-05 | Merck & Co., Inc. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
WO2004106276A1 (en) | 2003-05-30 | 2004-12-09 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
CA2532971A1 (en) | 2003-07-14 | 2005-01-27 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
AU2003267347A1 (en) * | 2003-09-10 | 2005-03-29 | Galapagos Genomics N.V. | Method of identifying a compound that changes the amyloid-beta precursor protein processing in a cell |
GB0403148D0 (en) * | 2004-02-12 | 2004-03-17 | Smithkline Beecham Corp | Chemical compounds |
JPWO2006016637A1 (en) * | 2004-08-11 | 2008-05-01 | 杏林製薬株式会社 | New cyclic aminobenzoic acid derivatives |
US20090036489A1 (en) * | 2005-03-22 | 2009-02-05 | Masahiro Nomura | Novel Cyclic Aminophenylalkanoic Acid Derivative |
EP2025674A1 (en) * | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
JPWO2009087981A1 (en) * | 2008-01-11 | 2011-05-26 | 株式会社Kri | Polymerizable compound and production method thereof |
EP3323818A1 (en) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014123205A1 (en) | 2013-02-06 | 2014-08-14 | 住友化学株式会社 | Condensed heterocyclic compound |
AU2016205361C1 (en) | 2015-01-06 | 2021-04-08 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
EP3310760B8 (en) | 2015-06-22 | 2022-10-19 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in s1p1 receptor-associated disorders |
MA47504A (en) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | COMPOUNDS AND TREATMENT METHODS FOR PRIMITIVE BILIARY ANGIOCHOLITIS |
CN108546245A (en) * | 2018-05-22 | 2018-09-18 | 绍兴文理学院 | A kind of preparation method of antiproliferative activity intermediate ML-098 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2169893A (en) * | 1984-12-28 | 1986-07-23 | Shionogi & Co | Benzofuran and benzothiophene derivatives |
WO2004010936A2 (en) * | 2002-07-30 | 2004-02-05 | Merck & Co., Inc. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4205080A (en) * | 1977-07-21 | 1980-05-27 | Shell Oil Company | 2,3-Dihydro benzofuran carboxamides |
US4213999A (en) * | 1979-06-07 | 1980-07-22 | Shell Oil Company | Inhibition of lipogenesis |
US4213998A (en) * | 1979-06-07 | 1980-07-22 | Shell Oil Company | Inhibition of lipogenesis |
DE3265715D1 (en) * | 1981-03-24 | 1985-10-03 | Fisons Plc | Anti srs-a carboxylic acid derivatives, processes for their production and pharmaceutical formulations containing them |
FR2645537B1 (en) * | 1989-04-05 | 1994-03-04 | Fabre Medicament Pierre | NOVEL SULFONAMIDES DERIVED FROM BENZOCYCLIC OR BENZOHETEROCYCLIC ACIDS, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION |
US5273999A (en) * | 1991-09-10 | 1993-12-28 | Hoffmann-La Roche Inc. | Carboxylic acid leukotriene B4 antagonists |
US5352690A (en) * | 1992-07-01 | 1994-10-04 | Eli Lilly And Company | 1,2,4-trioxygenated benzene derivatives useful as leukotriene antagonists |
US5324743A (en) * | 1992-12-10 | 1994-06-28 | Eli Lilly And Company | Leukotriene B4 antagonists |
JP3187611B2 (en) * | 1993-05-17 | 2001-07-11 | キヤノン株式会社 | Liquid crystal compound, liquid crystal composition containing the same, liquid crystal element having the same, display method and display device using them |
US5516917A (en) * | 1994-06-08 | 1996-05-14 | G. D. Searle & Co. | Leukotriene B4 antagonists |
EP1347755A2 (en) * | 2000-10-31 | 2003-10-01 | Merck & Co., Inc. | Benzopyrancarboxylic acid derivatives for the treatment of diabetes and lipid disorders |
-
2003
- 2003-07-25 CA CA002491733A patent/CA2491733A1/en not_active Abandoned
- 2003-07-25 WO PCT/US2003/023430 patent/WO2004010936A2/en active Application Filing
- 2003-07-25 DE DE60322075T patent/DE60322075D1/en not_active Expired - Lifetime
- 2003-07-25 AT AT03771907T patent/ATE400564T1/en not_active IP Right Cessation
- 2003-07-25 US US10/522,259 patent/US7524882B2/en not_active Expired - Fee Related
- 2003-07-25 AU AU2003256842A patent/AU2003256842B8/en not_active Ceased
- 2003-07-25 EP EP03771907A patent/EP1539136B1/en not_active Expired - Lifetime
- 2003-07-25 JP JP2004524883A patent/JP4475406B2/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2169893A (en) * | 1984-12-28 | 1986-07-23 | Shionogi & Co | Benzofuran and benzothiophene derivatives |
WO2004010936A2 (en) * | 2002-07-30 | 2004-02-05 | Merck & Co., Inc. | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
Non-Patent Citations (2)
Title |
---|
DATABASE HCAPLUS [online] COHEN ET AL: "3,4-dihydro-@h-1-benzopyran-2-carboxylic acids and related compounds as leukotriene antagonists", XP003001470, accession no. STN Database accession no. 1989:553565 * |
J. OF MEDICINAL CHEMISTRY, vol. 32, no. 8, 1989, pages 1842 - 1860 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933083B2 (en) | 2003-01-14 | 2015-01-13 | Arena Pharmaceuticals, Inc. | 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia |
US8362248B2 (en) | 2005-01-10 | 2013-01-29 | Arena Pharmaceuticals, Inc. | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
Also Published As
Publication number | Publication date |
---|---|
JP4475406B2 (en) | 2010-06-09 |
CA2491733A1 (en) | 2004-02-05 |
AU2003256842A1 (en) | 2004-02-16 |
US20050228044A1 (en) | 2005-10-13 |
DE60322075D1 (en) | 2008-08-21 |
EP1539136A2 (en) | 2005-06-15 |
WO2004010936A2 (en) | 2004-02-05 |
EP1539136B1 (en) | 2008-07-09 |
EP1539136A4 (en) | 2006-10-18 |
US7524882B2 (en) | 2009-04-28 |
AU2003256842B2 (en) | 2009-02-19 |
ATE400564T1 (en) | 2008-07-15 |
AU2003256842B8 (en) | 2009-06-18 |
JP2006500335A (en) | 2006-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004010936A3 (en) | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
EP1539137A4 (en) | Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders | |
WO2006060507A3 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
HUS1400011I1 (en) | Novel medicaments for the treatment of chronic obstructive pulmonary diseases | |
BR0109703A (en) | Piperazine Derivatives | |
WO2006033891A3 (en) | Compounds for the treatment of dyslipidemia and other lipid disorders | |
TW200507830A (en) | Bronchodilating β -agonist compositions and methods | |
WO2002074758A3 (en) | Novel amines as histamine-3 receptor ligands and their therapeutic applications | |
WO2006074265A3 (en) | Drug combination therapy and pharmaceutical compositions for treating inflammatory disorders | |
AU2003289888A1 (en) | Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders | |
IL165860A0 (en) | Administration of therapeutic viruses | |
WO2003053359A3 (en) | 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders | |
UY27462A1 (en) | QUINOLINE DERIVATIVES | |
AU2003213787A1 (en) | Compositions and methods for the treatment of anorectal disorders | |
AU2003286728A1 (en) | Compounds for the treatment of metabolic disorders | |
TW200732304A (en) | Piperidine derivatives | |
WO2005016327A3 (en) | Treatment of sleep disorders with cholinesterase inhibitors | |
AU2002332488A1 (en) | R-bambuterol, its preparation and therapeutic uses | |
SE9902267D0 (en) | New compounds | |
IL143985A0 (en) | New use of melagatran | |
ZA200107143B (en) | Use of saredutant and the pharmaceutically acceptable salts thereof to produce medicaments used to treat or prevent mood disorders, adjustment disorders or mixed anxiety-depression disorders. | |
WO2008033655A3 (en) | Compositions and methods for treating, controlling, reducing, ameliorating, or preventing allergy | |
WO2007134085A3 (en) | Isothiazolidines useful in the treatment of ocular hypertensive conditions | |
AU2003289652A1 (en) | The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion | |
SI1534296T1 (en) | Use of cilobradine or the pharmaceutically acceptable salts thereof for the treatment or prevention of heart failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2491733 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003256842 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10522259 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003771907 Country of ref document: EP Ref document number: 2004524883 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003771907 Country of ref document: EP |